Freeline Therapeutics Holdings Plc

NASDAQ FRLN

Data sourced from

and

Download Data

Freeline Therapeutics Holdings Plc Shareholders' Equity for the year ending December 31, 2022: USD 52.41 M

Freeline Therapeutics Holdings Plc Shareholders' Equity is USD 52.41 M for the year ending December 31, 2022, a -56.48% change year over year. Shareholders' Equity is the residual interest in the assets of a company after deducting liabilities, representing the shareholders' ownership claim.

Freeline Therapeutics Holdings Plc Shareholders' Equity for the year ending December 31, 2021 was USD 120.44 M, a -51.79% change year over year.
Freeline Therapeutics Holdings Plc Shareholders' Equity for the year ending December 31, 2020 was USD 249.80 M, a 194.03% change year over year.
Freeline Therapeutics Holdings Plc Shareholders' Equity for the year ending December 31, 2019 was USD 84.96 M, a 269.84% change year over year.
Freeline Therapeutics Holdings Plc Shareholders' Equity for the year ending December 31, 2018 was USD 22.97 M.

NASDAQ: FRLN

Freeline Therapeutics Holdings Plc

CEO	Mr. Michael J. Parini J.D.
IPO Date	Aug. 7, 2020
Location	United Kingdom
Headquarters	Stevenage Bioscience Catalyst, Stevenage, United Kingdom, SG1 2FX
Employees	152
Sector	Healthcare
Industry	Biotechnology

Description

Freeline Therapeutics Holdings plc, a clinical-stage biotechnology company, develops transformative adeno-associated virus (AAV) vector-mediated gene therapies. It develops FLT180a for the treatment of hemophilia B.; FLT201 for the treatment of Type 1 Gaucher disease; and FLT190 for the treatment of Fabry disease. in addition, it has research programs for systemic gene therapy. The company was founded in 2015 and is headquartered in Stevenage, the United Kingdom.

Key trends